CSOFT International, Inc., a leading provider of globalization and localization solutions, has officially announced the launch of the Globalization \u2022 Shenzhen 100, a research initiative that seeks to identify Shenzhen\u2019s brightest, most promising companies and rank their global readiness.<\/p>\n
Launched at the Four Seasons Hotel in Shenzhen\u2014a city with the 4th highest GDP in China\u2014the Shenzhen 100 is an innovative blend of hard data and qualitative indicators that provides a comprehensive ranking of global maturity among Shenzhen companies.<\/p>\n
Home to industry leaders Tencent, Mindray, BYD, DJI, and Huawei, as well as burgeoning local companies ZTE and TCL, Shenzhen\u2019s perpetual growth makes it an ideal location to launch such an initiative. With its leading position in China\u2019s Economic Reform in the last 30 years, Shenzhen has emerged as a leading city for China business development, high technology, and innovation. By identifying the city\u2019s most promising startup and globally maturing companies, the Shenzhen 100 seeks to become the go-to resource for investors, policymakers, and businesses for understanding Shenzhen\u2019s economic and entrepreneurial landscape, and guide them towards actionable solutions for stimulating innovation, encouraging global expansion, and promoting the city\u2019s long-term growth.<\/p>\n
\u201cI\u2019m excited to collaborate with CSOFT,\u201d said Shenzhen Vice Mayor Chen Biao, \u201cI am pleased to find the objectives of the Globalization \u2022 Shenzhen 100 are perfectly aligned with the city\u2019s future directions. This project will allow our city\u2019s entrepreneurs and innovators to thrive globally.\u201d<\/p>\n
Vice Mayor Chen Biao\u2019s speech was followed by a remark from Group Vice President of Mindray Biomedical Electronics David Yin. In his speech, Yin said he hopes the Shenzhen 100 project can help identify the ingredients for international success and assist companies as they tackle the risks and challenges of going global.<\/p>\n
The Shenzhen 100 is executed by CSOFT Globalization Institute (CGI), a research arm under CSOFT International that focuses on analyzing globalization maturity in four core industries\u2014healthcare, high technology, new energy, and consumer goods and services. Through its soft and hard data evaluation metrics, the CGI research team will analyze the global footprint of each participating company and perform a thorough survey of the firm\u2019s globalization management effectiveness. Based on this information, CGI will consolidate a Shenzhen 100 report to better understand the city\u2019s overall global competiveness and potential.<\/p>\n
This year\u2019s report, which will include a list of Top 10 Transformers, Top 10 Risers, and 100 globally mature or maturing Shenzhen companies, will be released at the Globalization \u2022 Shenzhen 100 Global Forum in June 2016. It will give participating companies an objective and thorough assessment of their future growth prospects in international markets.<\/p>\n
\u201cThe entrepreneurial spirit of Shenzhen gives me confidence that more and more global innovators are going to come out of this mega city,\u201d said Shunee Yee, President and CEO of CSOFT International, Inc. \u201cShenzhen has the potential to become the world\u2019s next Silicon Valley but in order to do that, it needs to have at least 100 influential brands, and that\u2019s what this project is all about. We are not only here to inspire the future, but to also position the city\u2019s most opportune companies along the path to globalization.\u201d<\/p>\n
For more than a decade, CSOFT International has provided superior globalization solutions for Fortune 500 companies and leading businesses worldwide. To execute this ambitious endeavor, CSOFT has partnered with the Shenzhen government and its economic promotion bureaus. To learn more about the Globalization \u2022 Shenzhen 100, please visit\u00a0http:\/\/csoftintl.com\/shenzhen100<\/a> or email shenzhen100@csoftintl.com<\/a>.<\/p>\n\n CSOFT Health Sciences, leaders in clinical trial localization, provides AI\/ML-enabled medical translation services for all phases of the drug and medical device product lifecycle, from development to post-launch. We also specialize in DCT solutions, linguistic validation, and CTD\/eCTD submissions with the FDA, EMA, and NMPA. Our operations are certified in ISO 17100:2015, ISO 9001:2015, and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of MMA, NDA, CTA, and Medical Device Application submissions. www.csoftintl.com<\/u><\/a><\/p>\n \n <\/div>\n\r\n About CSOFT Health Sciences<\/h3>\n